γδ T Cell Therapy Development for LymphomasOnline Inquiry
Creative Biolabs is a global company that focuses on T cell therapy discovery and development. With our extensive experience and unique platform, we can provide a series of gamma delta (γδ) T cell development services based on a wide variety of state-of-art technologies. We are proud to partner with our clients on the journey of bringing you novel γδ T cell therapy to the market.
Introduction to Lymphomas
Lymphoma is a type of cancer that is caused by the uncontrolled growth of lymphocytes in the lymph system. Lymphocytes are a group of white blood cells that play an important role in regulating immune responses to fight different infections. Lymphoma can spread to most parts of the human body, including neck, liver, lung, thymus, spleen, lymph nodes, and bone marrow.
Nowadays, lymphoma has been classified into two main types: Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma is the most common lymphoma that accounts for 96% of all cases. Meanwhile, the stage of lymphoma has also been identified based on how far the tumor has spread, including low-grade lymphoma, intermediate-grade lymphoma, as well as high-grade lymphoma. The symptoms of early lymphoma are composed of fever, cough, rash, fatigue, and bone pain. Previous studies have revealed that people with immunodeficiency, family history, infection, or autoimmune diseases have a greater risk for lymphoma. Till now, a wide variety of therapeutic strategies have been generated and broadly used in clinics. For example, surgery, radiation therapy, stem cell transplantation, and chemotherapy have been considered routine treatments for lymphoma. Besides, novel immunotherapy and targeted therapy have also proven huge potential in cancer therapy, and they should be an attractive tool for treating lymphoma in the future.
γδ T Cell for Lymphoma Treatment
γδ T cells are essential to the production and proliferation of lymphokines in humans. Recent researchers have indicated that γδ T cell is also associated with the poor prognosis and low survival rate of patients with different kinds of lymphomas, such as cutaneous T-cell lymphoma and hepatosplenic T-cell lymphoma (HS-TCL). As a result, the identification of the T cell phenotype has become a priority in treating lymphoma. Furthermore, a large number of γδ T cell-based modification techniques have been designed and utilized to develop novel immunotherapies for lymphoma treatment.
By continuing growth in response to the requirements of our clients, Creative Biolabs is dedicated to harnessing the unique properties of γδ T cells to improve therapeutic effect and survival rates among patients with lymphomas. Our exclusive isolation and expansion protocols can selectively generate and modify γδ T cell subpopulations suitable for specific lymphoma types. For instance, different Vδ subsets of γδ T-cells, like Vδ1 and Vδ2, have been widely screened and engineered for improving antigen expression in clinical applications. Also, we have established a comprehensive γδ chimeric antigen receptor (CAR) T-cell platform, from fully understanding and identifying the requirement of your γδ CAR-T cell, to clinical-stage γδ CAR-T cell construction. In a recent study, CD19-directed γδ CAR-T cells have been developed for the killing and clearance of non-Hodgkin lymphoma. The results have indicated that γδCAR-T cells can target CD19 antigen-negative tumor cells and produce high-purity and effective effector cells against lymphoma.
Fig.1 Major receptor-ligand interactions between Vδ2/non-Vδ2 γδ T cells and tumor cells/antigen-presenting cells. (Kabelitz, 2020)
As a leader in the field of T cell therapy development, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide the best-customized services to help you design and evaluate the safety and efficacy of your γδ T cell therapy projects. We have established an advanced γδ T cell therapy platform that enables us to help build and establish a long-term vision with commercialization in mind. If you are interested in our services, please contact us or send us an inquiry.
- Kabelitz, D., et al. Bacteroides: Cancer immunotherapy with γδ T cells: many paths ahead of us. Cellular & Molecular Immunology. 2020, 1-15.